These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 8351680)
1. [Economic aspects of pharmacovigilance in the pharmaceutical industry]. Abadie E; Souetre E Therapie; 1993; 48(2):125-7. PubMed ID: 8351680 [TBL] [Abstract][Full Text] [Related]
2. Drug therapy: safety, effectiveness, and economics. Brandys J Przegl Lek; 2001; 58(4):226-8. PubMed ID: 11450340 [TBL] [Abstract][Full Text] [Related]
3. Economic advantage of pharmacogenomics - clinical trials with genetic information. Ohashi W; Mizushima H; Tanaka H Stud Health Technol Inform; 2008; 136():585-90. PubMed ID: 18487794 [TBL] [Abstract][Full Text] [Related]
4. Pharmacoeconomics of adverse drug reactions. Lundkvist J; Jönsson B Fundam Clin Pharmacol; 2004 Jun; 18(3):275-80. PubMed ID: 15147278 [TBL] [Abstract][Full Text] [Related]
5. Are drug too expensive in Canada? No. Williams R; Marion J Can Fam Physician; 2006 May; 52():573-6, 578-81. PubMed ID: 16739822 [No Abstract] [Full Text] [Related]
6. [Economic impact of adverse drug effects. Some reflections]. Spreux A; Chichmanian RM; Castot A Therapie; 1992; 47(5):385-8. PubMed ID: 1299976 [TBL] [Abstract][Full Text] [Related]
7. Drug costs: research and development costs: the great illusion. Prescrire Int; 2004 Feb; 13(69):32-6. PubMed ID: 15055226 [TBL] [Abstract][Full Text] [Related]
9. The medical profession and the pharmaceutical industry: when will we open our eyes? Masters S Med J Aust; 2004 Oct; 181(8):459; discussion 459. PubMed ID: 15612086 [No Abstract] [Full Text] [Related]
11. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace. Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999 [TBL] [Abstract][Full Text] [Related]
12. Are drugs too expensive in Canada? Yes. Lexchin J Can Fam Physician; 2006 May; 52(5):573-6, 578-81. PubMed ID: 16739821 [No Abstract] [Full Text] [Related]
13. In search of sustainability: process R&D in light of current pharmaceutical industry challenges. Federsel HJ Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405 [TBL] [Abstract][Full Text] [Related]
14. Procedures and methods of benefit assessments for medicines in Germany. Bekkering GE; Kleijnen J Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness data on biologics needed. Sheridan C; Katsnelson A Nat Biotechnol; 2005 Mar; 23(3):272-3. PubMed ID: 15765069 [No Abstract] [Full Text] [Related]
16. A prescription for cutting health care costs. Caring; 1992 Nov; 11(11):10-4. PubMed ID: 10121247 [TBL] [Abstract][Full Text] [Related]
17. The price of pills. Does it really take $897 million for a new therapy? Ezzell C Sci Am; 2003 Jul; 289(1):25. PubMed ID: 12840941 [No Abstract] [Full Text] [Related]
18. Pharmaceutical industry overview: optimal drug therapy. Blake P Can J Clin Pharmacol; 2001; 8 Suppl A():48A-52A. PubMed ID: 11586380 [TBL] [Abstract][Full Text] [Related]
19. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification. Smart A; Martin P Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):583-601. PubMed ID: 16980196 [TBL] [Abstract][Full Text] [Related]
20. Documentation and evaluation of adverse drug reactions (ADR)--contribution from a poison information center. Mey C; Hentschel H; Hippius M; Balogh A Int J Clin Pharmacol Ther; 2002 Mar; 40(3):102-7. PubMed ID: 11911597 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]